Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development

Recent study provides proof of concept for using novel scoring system
to define IBD-related changes in microbiome

VANCOUVER, British Columbia–(BUSINESS WIRE)–#IBD–With a growing body of science linking gut microbiota to inflammatory
bowel disease (IBD), a need exists in clinical settings to understand
changes in the gut microbial community as they relate to IBD and its
management.

Two leading microbiome companies, Rebiotix (part of the Ferring
Pharmaceuticals Group) and Microbiome Insights, are collaborating to
validate one such tool: a proprietary analysis to determine how closely
a patient’s microbiome resembles that of someone with IBD. Microbiome
Insights’ bioinformaticians developed an IBD Microbiome Score, based on
a vast dataset of over 1600 individuals with IBD and healthy controls.
The metric combines the latest understandings of the gut microbiome as a
complex ecosystem with information on hundreds of taxa in the bacterial
community, rather than the presence or absence of specific taxa. Based
on fecal microbial characterization by sequencing, the IBD Microbiome
Score can be assigned for each individual patient at diagnosis and at
different times throughout treatment, making the Score practical for
clinical use. Leveraging Rebiotix’s proprietary Microbiota Restoration
Therapy™ (MRT) drug development platform, the Score is being evaluated
in active clinical trials to treat IBD.

“The microbiome field is enormously complex,” says Dr. Ken Blount,
Rebiotix’s Chief Scientific Officer. “With the use of the first-in-class
Rebiotix MRT platform continuing to expand into complex conditions such
as IBD, it is critical to have strong, scientifically-validated tools to
understand the dynamics of the microbiomes changes within our patients.
We’ve seen first-hand how the novel platform and expertise of Microbiome
Insights has the potential to rapidly advance not only our understanding
of the impact of MRT on patients, but also to uncover valuable
microbiome findings for the entire industry.”

“Our scientific team has consulted with leading gastroenterologists to
explore ways of leveraging the science on the microbiome and IBD in the
clinical setting,” says Microbiome Insights CEO Malcolm Kendall. “Now we
have developed the first scientifically robust tool for tracking the
microbiome of people with IBD and understanding its link to clinical
outcomes. The ability to work with Rebiotix on this path to discovery
underscores the future utility of our platform in the clinical setting.”

The companies are continuing to explore applications of Rebiotix
interventions and Microbiome Insights’ personal health platform in other
microbiome-related diseases.

About Rebiotix

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a
late-stage clinical microbiome company focused on harnessing the power
of the human microbiome to revolutionize the treatment of debilitating
diseases using drug products built on its pioneering Microbiota
Restoration Therapy™ (MRT) platform. The MRT platform is a standardized,
stabilized drug technology that is designed to rehabilitate the human
microbiome by delivering a broad consortium of live microbes into a
patient’s intestinal tract via a ready-to-use and easy-to-administer
format. For more information on Rebiotix and its pipeline of human
microbiome-directed therapies, visit www.rebiotix.com.

About Microbiome Insights

Microbiome Insights, Inc. is a global leader providing end-to-end
services for microbiome DNA sequencing, including state-of-the-art
bioinformatic analysis. Based in Vancouver, Canada, the company’s
customized suite of services enables researchers and clinicians to
easily and effectively include microbiome analysis in studies across a
range of human, animal, agricultural and environmental applications. The
multidisciplinary team of researchers and knowledge leaders at the
company provide access to decades of expertise in traditional sciences
such as ecology, microbiology, infectious diseases, and genetics.
Microbiome Insights’ award-winning team is committed to providing
clients with fast, dependable, cost-effective results. Learn more: microbiomeinsights.com

Contacts

KC Microbiome Communications Group
Kristina Campbell, 778
350 5993

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.